Pharmaceutical company Sanofi has reached an agreement with the European Commission to resolve allegations regarding misleading marketing practices for its influenza vaccines. The deal concludes an investigation into whether the French firm used deceptive communication to boost sales of its products in Germany and France.
- The European Commission launched an investigation into Sanofi for potential abuse of its dominant market position.
- Regulators scrutinized whether the company disseminated misleading information to undermine a rival flu vaccine.
- Sanofi pledged to correct its communications to address these competition concerns.
- The agreement allows the company to avoid a potential fine of up to 10% of its global annual turnover.
The regulator accepted these commitments, effectively closing the antitrust case against the manufacturer.
#Sanofi #EU #Healthcare #Antitrust @EU_Commission